drugset / Trial / NCT00736879
Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on diet and exercise alone. The safety of this treatment will also be studied
Timeline
- Start
- 2008-09-22
- Primary completion
- 2009-12-29
- Completion
- 2009-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 1 mg | Oral |
| Subject | Dapagliflozin | Small molecule | 2.5 mg | Oral |
| Subject | Dapagliflozin | Small molecule | 5 mg | Oral |